Premium
Should Radiofrequency Therapy Be Performed in Every Symptomatic Patient with Supraventricular Tachycardia? (Pro Drug Position)
Author(s) -
ANDRESEN DIETRICH,
BEHRENS STEFFEN,
BRÜGGEMANN THOMAS,
SCHRÖDER ROLF
Publication year - 1993
Publication title -
pacing and clinical electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 101
eISSN - 1540-8159
pISSN - 0147-8389
DOI - 10.1111/j.1540-8159.1993.tb01639.x
Subject(s) - medicine , supraventricular tachycardia , radiofrequency ablation , tachycardia , refractory (planetary science) , drug , pharmacotherapy , cardiology , catheter ablation , anesthesia , ablation , pharmacology , physics , astrobiology
The indication for treatment of paroxysmal supraventricular tachycardia depends on the frequency and severity of the tachycardia attacks. If the tachycardia attacks are mildly symptomatic and occur only once or twice a year, there is no indication for either continuous drug therapy or radiofrequency oblation. The only therapeutic measure required is termination of each acute event. If symptoms occur frequently, long‐term antiarrhythmic drug therapy is then indicated and will be effective for chronic prophylaxis in most individuals with a low risk of proarrhythmic events. Only in patients with severe or life‐threatening symptoms or cases refractory to drug therapy would radiofrequency ablation possibly be justified.